Pandion emerged with former Pfizer and Biogen execs; Hikma tapped ex-Fresenius scientist as CSO; Ipsen hired ex-Amgen oncology exec.

Van Herk Investments thinks Novo’s recent offer was too low, but it will encourage Ablynx to enter talks if a sufficiently sweetened bid is received.

Marshall has served as Sosei CSO since it bought Heptares but is now departing to take on a senior role at another business.

European researchers discovered how drugs bind to the enzyme DHODH, which could lead to more selective cancer drugs.

Gilead and its $12 billion biotech buy Kite Pharma have teamed up with Pfizer to work on a Yescarta-utomilumab combo test in certain blood cancers.

In this week's EuroBiotech Report, Merck KGaA pens cancer pact, MDC details U.K. drug discovery goals and more.

In our EuroBiotech roundup this week, TxCell gets funding for CAR-Treg program, ETX strikes AI deals and Transgene advances hepatitis B program.

Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year.

Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.